Literature DB >> 22628389

The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.

Mitchell T Wallin1, William J Culpepper, Parisa Coffman, Sarah Pulaski, Heidi Maloni, Clare M Mahan, Jodie K Haselkorn, John F Kurtzke.   

Abstract

We characterize here a new nationwide incident cohort of multiple sclerosis from the US military-veteran population. This cohort provides an update to the only other US nationwide incidence study of multiple sclerosis performed during the 1970s. Medical records and data from the Department of Defense and Department of Veterans Affairs for cases of multiple sclerosis who served in the military between 1990, the start of the Gulf War era, and 2007 and who were service-connected for this disorder by the Department of Veterans Affairs from 1990 on, were reviewed. A total of 2691 patients were confirmed as having multiple sclerosis: 2288 definite, 190 possible, 207 clinically isolated syndrome and six neuromyelitis optica. Overall racial categories were White, Black and other, which included all Hispanics. There were 1278 White males and 556 females; 360 Black males and 296 females; and 200 others, 153 (77%) of whom were Hispanic. Mean age at onset of 30.7 years did not differ significantly by race or sex. Age at onset was 17-50 years in 99%, the same age range as 99% of the military. Average annual age specific (age 17-50 years) incidence rates per 100 000 for the entire series were 9.6 with 95% confidence interval of 9.3-10.0. Rates for Blacks were highest at 12.1 with confidence interval 11.2-13.1, Whites were 9.3 (interval 8.9-9.8) and others 6.9 (interval 6.0-7.9). For 83 Hispanics defined for 2000-07, the rate was 8.2 (interval 6.5-10.1). Much smaller numbers gave rates of 3.3 for Asian/Pacific Islanders and 3.1 for native Americans. Rates by sex for Whites were 7.3 and 25.8 male and female, respectively, for Blacks 8.4 and 26.3, and for Hispanics 6.6 and 17.0. Rates by service were high for Air Force (10.9) and Army (10.6), medium for Navy (9.1) and Coast Guard (7.9), and low for Marines (5.3). Relative risk of multiple sclerosis was 3.39 female:male and 1.27 Black:White. These new findings indicate that females of all races now have incidence rates for multiple sclerosis some three times those of their male counterparts and that among these groups, Blacks have the highest and others (probably including Hispanics) the lowest incidence rates regardless of sex or service. The low rate for Marines is unexplained. This Gulf War era multiple sclerosis cohort provides a unique resource for further study.

Entities:  

Mesh:

Year:  2012        PMID: 22628389     DOI: 10.1093/brain/aws099

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  61 in total

Review 1.  Multiple Sclerosis in Latin Americans: Genetic Aspects.

Authors:  Victor M Rivera
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08       Impact factor: 5.081

Review 2.  Genetic determinants of risk and progression in multiple sclerosis.

Authors:  Alessandro Didonna; Jorge R Oksenberg
Journal:  Clin Chim Acta       Date:  2015-02-04       Impact factor: 3.786

3.  An ImmunoChip study of multiple sclerosis risk in African Americans.

Authors:  Noriko Isobe; Lohith Madireddy; Pouya Khankhanian; Takuya Matsushita; Stacy J Caillier; Jayaji M Moré; Pierre-Antoine Gourraud; Jacob L McCauley; Ashley H Beecham; Laura Piccio; Joseph Herbert; Omar Khan; Jeffrey Cohen; Lael Stone; Adam Santaniello; Bruce A C Cree; Suna Onengut-Gumuscu; Stephen S Rich; Stephen L Hauser; Stephen Sawcer; Jorge R Oksenberg
Journal:  Brain       Date:  2015-03-28       Impact factor: 13.501

4.  Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.

Authors:  Luis Hernandez; Malinda O'Donnell; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

5.  Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania.

Authors:  Michael H Barnett; James G McLeod; Simon R Hammond; John F Kurtzke
Journal:  J Neurol       Date:  2016-02-25       Impact factor: 4.849

6.  Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study.

Authors:  Natalia Gonzalez Caldito; Shiv Saidha; Elias S Sotirchos; Blake E Dewey; Norah J Cowley; Jeffrey Glaister; Kathryn C Fitzgerald; Omar Al-Louzi; James Nguyen; Alissa Rothman; Esther Ogbuokiri; Nicholas Fioravante; Sydney Feldman; Ohemaa Kwakyi; Hunter Risher; Dorlan Kimbrough; Teresa C Frohman; Elliot Frohman; Laura Balcer; Ciprian Crainiceanu; Peter C M Van Zijl; Ellen M Mowry; Daniel S Reich; Jiwon Oh; Dzung L Pham; Jerry Prince; Peter A Calabresi
Journal:  Brain       Date:  2018-11-01       Impact factor: 13.501

Review 7.  The immunogenetics of multiple sclerosis: A comprehensive review.

Authors:  Jill A Hollenbach; Jorge R Oksenberg
Journal:  J Autoimmun       Date:  2015-07-02       Impact factor: 7.094

8.  Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.

Authors:  Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

Review 9.  Multiple sclerosis in men: management considerations.

Authors:  Riley Bove; Allison McHenry; Kerstin Hellwig; Maria Houtchens; Neda Razaz; Penelope Smyth; Helen Tremlett; A D Sadovnick; D Rintell
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

Review 10.  The initiation and prevention of multiple sclerosis.

Authors:  Alberto Ascherio; Kassandra L Munger; Jan D Lünemann
Journal:  Nat Rev Neurol       Date:  2012-10-09       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.